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Cancer Therapy: Preclinical
Reduced Dose and Intermittent Treatment with Lapatinib and
Trastuzumab for Potent Blockade of the HER Pathway in
HER2/neu-Overexpressing Breast Tumor Xenografts
Mothaffar F. Rimawi1,2,3, Lisa S. Wiechmann4, Yen-Chao Wang1, Catherine Huang1,5,
Ilenia Migliaccio1, Meng-Fen Wu2, Carolina Gutierrez1, Susan G. Hilsenbeck1,2, Grazia Arpino1,
Suleiman Massarweh6, Robin Ward1, Robert Soliz1, C. Kent Osborne1,2,3,5, and Rachel Schiff1,2,3,5
Abstract
Purpose: We have shown that incomplete blockade of the human epidermal growth factor (HER)
pathway is a mechanism of resistance to treatment with trastuzumab (T) in HER2-overexpressing tumor
xenografts. We now investigate whether the addition of lapatinib (L), a dual HER1/2 kinase inhibitor, to T
results in more potent inhibition of the pathway and therefore inhibition of tumor growth, and whether
reduced dose and intermittent treatment with the combination is equally effective.
Experimental Design: Nude mice bearing HER2-overexpressing MCF7/HER2–18 or BT-474 xenograft
tumors were treated with L and T, alone or in various combinations with other HER inhibitors. L þ T for
short duration (14 and 42 days), intermittent administration (14 days on/off), and reduced dosing (half
dose) was also investigated. Inhibition of tumor growth, downstream signaling, proliferation, and
induction of apoptosis were assessed. All statistical tests were two-sided.
Results: L þ T was the most effective regimen in both MCF7/HER2–18 and BT-474 xenografts with
complete regression (CR) of tumor observed in all mice. Intermittent and reduced dose treatment (1/2 dose)
resulted in high rates of CR and low rates of tumor recurrence that were comparable to full dose continuous
treatment. L þ T resulted in significantly reduced downstream signaling and proliferation, and increased
apoptosis.
Conclusions: L þ T is a potent and effective combination even when given in reduced dose or
intermittent schedule potentially resulting in lower toxicity and reduced cost if translated to patients.
These findings warrant timely clinical testing. Clin Cancer Res; 17(6); 1351–61. 2011 AACR.
Background
Human epidermal growth factor receptor 2 (c-ErbB2,
HER2/neu, or HER2) is a clinically important therapeutic
target in patients with HER2-overexpressing breast cancers.
It is a component of a robust and complex network
comprised of 4 tyrosine kinase receptors, HER1–4, which
can be activated by multiple ligands which induce homo-
and heterodimerization. HER2 does not have a ligand and,
therefore, is activated by partnering with itself or another
familymember (1–7). The pathway can also be activated by
alterations downstream of the HER receptor layer including
loss of the tumor suppressor gene PTEN or activating
mutations in PI3K thatmay cause resistance to trastuzumab
(T; refs. 8–10).
Trastuzumab, a humanized monoclonal antibody direc-
ted at the HER2 extracellular domain, inhibits this path-
way. Its use resulted in significant reductions in recurrence
and mortality in patients with HER2-positive breast cancer
(11, 12). However, de novo and acquired drug resistance
remain a clinical problem (13, 14).
Lapatinib (L), a dual HER1 and HER2 tyrosine kinase
inhibitor, is approved for treatment of metastatic HER2-
positive breast cancer and is being investigated in various
clinical settings. It would be expected to effectively block
the receptor layer by inhibiting signals generated by multi-
ple dimer pairs (15–17). On the basis of our early report
and data from other groups, L combined with T is now
being studied in the clinical setting (16–20).
We investigated the effect of L alone or in combination
with other anti-HER agents in 2 xenograft models and
identified L þ T as the most potent combination. Given
concerns about the toxicity and cost of long-term
treatment with these expensive agents, we further
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investigated reduced dosing and intermittent scheduling of
this potent combination.
Methods
Reagents, hormones, and antibodies
Sixty-day release, 17b-estradiol pellets (E2; 0.36 mg) were
purchased from Innovative Research and tamoxifen citrate
(Tam; 500 mg subcutaneously in peanut oil, 5 d/wk) was
purchased from Sigma. L (100 mg/kg free base active ingre-
dient via gavage in 1% Tween once a day, 5 d/wk) was
provided by GlaxoSmithKline. Gefitinib (G; 100 mg/kg via
gavage in 1% Tween 80 5 d/wk) was provided by AstraZe-
neca. T (10 mg/kg intraperitoneally in sterile H2O twice a
week) and pertuzumab (P; 12 mg/kg intraperitoneally the
first week and then 6 mg/kg intraperitoneally in 1% sterile
PBS weekly) were provided by Genentech. Antibodies used
for immunoblotting were as follows: phosphorylated (p)-
Tyr1248-HER2(Millipore); totalHER2, total andphosphory-
lated forms of AKT (Thr308), extracellular signal regulated
kinase 1 and 2, mitogen activated protein kinase (MAPK;
Thr202/Tyr204), and b-actin (Cell Signaling Technology).
Immunohistochemistry
Tumor tissue was fixed in 4% neutral-buffered formalin
overnight before processing and paraffin embedding. Immu-
nohistochemistry (IHC) was done on 4-m sections from
randomly arrayed in 4-mm core tissue arrays. Bromodeox-
yuridine (BrDU) labeling of tumor cell nuclei was visualized
by staining with BrDU antibody (Biogenic). Additional sec-
tions were used to stain apoptotic cells using the cleaved
caspase 3/7 antibody (Cell Signaling Technology) and for
activated MAPK using the p-MAPK antibody (Cell Signaling
Technology) as previously described (21, 22).
Tumors were scored by percent of positive cells for BrDU
and cleaved caspase 3/7 staining, and by Allred score for the
activated MAPK staining (21, 23).
Tumor extracts and immunoblots
Frozen tumors from the different treatment groups were
homogenized in lysis buffer containing 1% Triton X-100,
50mmol/LHEPES, pH 7.4, 150mmol/L NaCl, 1.5mmol/L
MgCl2, 1 mmol/L EGTA, 100 mmol/L NaF, 10 mmol/L
NaPPi, 10% glycerol, 1 mmol/L phenylmethylsulfonyl-
fluoride, 1 mmol/L Na3VO4, 10 mg/mL aprotinin, and
1 protease inhibitor cocktail (Roche Molecular Biochem-
icals). Tumor lysates were microcentrifuged at 14,000  g
for 10 minutes at 4C. Cell supernatants were aliquoted
and stored at 70C. Protein concentration was measured
by the Bio-Rad Protein Assay kit (Bio-Rad Laboratories).
Equivalent amounts of protein (25 mg) from each sample
were separated by electrophoresis on 8% to 16% polya-
crylamide gels containing SDS (SDS-PAGE), and trans-
ferred by electroblotting onto nitrocellulose membranes
(Schleicher & Schuell) followed by immunobloting with
the specific antibodies as previously described (21). For all
antibodies the reaction was in Odyssey Blocking Buffer (LI-
COR Biosciences)þ 0.05% Tween-20 overnight at 4C. The
blots were washed 3 times in PBS with Tween-20 (PBST)
and then incubated for 1 hour at room temperature with
fluorescently labeled secondary antibody inOdyssey Block-
ing Buffer þ 0.05% Tween-20. The blots were then washed
in PBST, after which the labeled protein was quantified by
Odyssey Infrared Imaging System. Gels were reproduced at
least twice. In each tumor sample, protein levels were
corrected with b-actin (protein levels/actin levels  102).
Means of corrected expression levels were calculated and
fold changes compared with the endocrine treatment alone
group (without anti-HER therapy) are presented for each
treatment group. Representative blots are presented.
Xenograft studies
MCF/HER2–18 (HER2 transfected) and BT-474 (gene-
amplified for HER2) cells were maintained as described
(21, 24, 25). Animal care was in accordance with institu-
tional guidelines. MCF7/HER2–18 and BT-474 xenografts
were established in ovariectomized 5- to 6-week-old athy-
mic mice (Harlan Sprague Dawley) supplemented with
estrogen pellets by inoculating subcutaneously (5  106
cells) as described previously (21, 26). When tumors
reached the size of 200–250 mL (2–4 weeks), mice bearing
MCF/HER2–18 xenografts were randomly allocated to
continued estrogen (E2), estrogen deprivation alone
(ED) by removal of the estrogen pellets, or ED þ Tam
(26). Mice treated with EDþ Tamwere then randomized to
receive L or T alone, Lþ T, double dose L (2L), LþG, or Lþ
P. Mice treated with E2 and mice treated by ED were
randomly allocated to vehicle, L, T, or L þ T. Another
group was treated with continued E2, Tam, and Lþ T. Each
treatment group contained a minimum of 12 mice. Groups
of animals destined for molecular studies contained a
minimum of 8 additional mice.
Animals bearing BT-474 xenografts were randomly allo-
cated to E2, ED alone, ED þ L, EDþ T, EDþ Lþ T, and E2
þ L þ T. Additional mice were treated with L þ T for short
duration (14 and 42 days), intermittent administration
Translational Relevance
We have previously shown that combination anti-
HER therapies are more effective than single agents in
HER2-overexpressing breast cancermodels by providing
more potent blockade of downstream signaling. The
present preclinical study investigates drugs targeting the
pathway by different mechanisms and examines differ-
ent doses and schedules in HER2-overexpressing xeno-
grafts. Lapatinib þ trastuzumab was the most potent
combination in blocking HER signaling, and it led to
tumor eradication in most mice. Interestingly, intermit-
tent or reduced dosing schedules were just as effective as
continuous therapy.
These data provide a rationale for clinical trials of
intermittent or reduced doses of lapatinib þ trastuzu-
mab therapy, strategies that, if as effective as continuous
full dose treatment, would dramatically reduce the
toxicity and cost of treatment.
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(14 days on/14 days off), and dose reduction (1/2L þ 1/2T).
Each treatment group contained a minimum of 10 mice.
Groups of animals destined for molecular studies con-
tained a minimum of 6 additional mice.
Tumor volumes were measured weekly as described
previously (21, 26). Mice were sacrificed and tumors were
harvested after short-term treatment (3 days) for analysis of
associated biomarkers, when they reached the size of 1000
mL, or at the end of the experiments. Each tumor analyzed
was from a different mouse; tumor tissues were removed
from each individual mouse and kept at 190C or for-
malin-fixed and paraffin embedded for later analyses.
Statistical analysis
Tumor growth curves were constructed using the mean
tumor volume at each time point with error bars represent-
ing the standard error of the mean. Animals that died of
other causes prior to the first animal developing a resistant
tumor were not included in the calculation of tumor
growth curves but were included in all other analyses. Time
to treatment resistance (TTR), defined as time in days to
developing tumors that are 2.5 times the volume at base-
line, was calculated for each mouse. In the experiments
with intermittent scheduling and reduced dosing, to detect
small but significant differences, the rate of tumor progres-
sion was measured at day 315 (TP315). A tumor was
considered to have progressed if 2 consecutive 10% or
greater increases in tumor size were detected starting from
a tumor size greater than 0.
Themedian TTR along with 95%CI were estimated using
the Kaplan–Meier method and compared by generalized
Wilcoxon test. P values for the xenograft studies were
adjusted for multiple comparisons using the Hommel
method to control for type I error when appropriate.
Complete regression (CR) was defined as complete tumor
disappearance for at least 3 consecutive measurements. CR
rates were calculated based on the total number of animals
treated in each group. Pairwise comparisons of tumor
proliferation and survival pathways based on IHC assess-
ments weremade using nonparametric Wilcoxon rank-sum
test. All statistical tests were two-sided.
Results
Lþ T combination in MCF7/HER2–18 tumors
As we have previously shown, in MCF7/HER2–18 tumor
xenografts concurrent targeting of the HER pathway and
the estrogen receptor (ER) greatly enhances therapeutic
efficacy (21). Although treatment with L alone, T alone,
or L þ T significantly delayed estrogen stimulated growth
and prolonged TTR in this model (Fig. 1A and Table 1), the
benefit was short-lived and tumor growth resumed.
Figure 1B shows the growth curves in tumors treated with
tamoxifen alone or along with HER inhibitors, and Table 1
shows the CR rate and the median TTR in these tumors. As
previously shown, this xenograft model is tamoxifen sti-
mulated due to, at least in part, crosstalk between non-
nuclear ER and the HER pathway (24, 27–29). When
tamoxifen-treated mice were treated with single anti-HER
agents (Tam þ L and Tam þ T), CR occurred in some mice
and TTRwas significantly prolonged (Table 1). However, in
mice treated with the combination (Tam þ L þ T), CR was
observed in 86% of mice (12/14; Fig. 1B). The median TTR
was significantly prolonged with this combination to
229 days (95% CI: 170–342) although resistance to this
combination eventually emerged. This combination was
effective even in the presence of estrogen (E2 þ Tam þ L þ
T;Fig. 1C and Table 1).
In addition, ED was used to target ER to mimic aroma-
tase inhibitor therapy in postmenopausal patients. Figure
1D shows that the addition of L or T to ED improved the CR
rate and the TTR. However, the most effective regimen was
ED combined with Lþ T. CR was observed in 85% (11/13)
of tumors and after 231 days, only 2 mice had resistant
tumors (P < 0.0001, 0.039, and 0.035 compared with ED,
EDþ L, and EDþ T, respectively; generalizedWilcoxon test
with Hommel adjustment).
After 231 days, L þ T treatment was stopped in 9 mice
with no evidence of tumor and they were randomized
to retreatment with estrogen (4 mice) or continued ED
(5 mice), and followed for 70 additional days. Two of the
4 mice retreated with estrogen had tumor regrowth,
whereas none of the mice continued on ED showed re-
growth of tumors.
Other inhibitors of the HER pathway
in MCF7/HER2–18 tumors
To better understand the mechanism of action and
potency of L þ T, we evaluated other HER targeting regi-
mens (Fig. 1E). To exclude the possibility that L þ T was
more effective than L alone because of suboptimal dosing
of L and based on published data suggesting that higher
dose of L may be more effective (30, 31), 1 group of mice
was given a double dose of L (200 mg/kg, 5 d/wk; Tam þ
2L). Because L is a less potent inhibitor of HER1 than
HER2, another group was treated with L and G for more
potent epidermal growth factor receptor inhibition (Tamþ
L þ G). Finally, L was combined with P (2C4; Genentech),
a monoclonal antibody that inhibits HER2 dimerization,
to determine if this potent inhibitor could replace T in the
combination (Tam þ L þ P; Table 1).
As shown in Table 1 and Figure 1E, doubling the L dose
(Tam þ 2L) did not improve efficacy and although several
animals had only small residual tumors, none achieved CR.
The median TTR was 150 days [95% CI: 122–not achieved
(NA)]. Adding G to L (Tam þ L þ G) also did not improve
the CR rate (8%) or the median TTR (147 days, 95% CI:
109–NA). In comparison with Tam þ L þ T, the substitu-
tion of P for T (Tam þ L þ P) led to inferior results with
lower tumor regression rate (14%) and a shorter median
TTR (178 days, 95% CI: 138–NA). Although the P value
adjusted for multiple comparisons did not achieve statis-
tical significance when comparing TTR in the Tam þ L þ P
group to the Tam þ L þ T group, the notable difference in
CR (Tam þ L þ P, 14%; Tam þ L þ T, 86%) suggests that
Tam þ L þ T is the superior regimen.
Lapatinib and Trastuzumab in HER2-Positive Breast Cancer
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L þ T combination in BT-474 tumors
The BT-474 cell line is an ER-positive human breast
cancer cell line that is naturally amplified for HER2
(25). As we have shown before, established BT-474 xeno-
graft tumors are estrogen independent despite expressing
ER and grow similarly with and without estrogen (Fig. 2A;
ref. 21). L and T alone led to complete tumor regression in
45% (5/11) and 91% (10/11) of ED-treated mice, respec-
tively. However, BT-474 tumors were exquisitely sensitive
to Lþ T. All tumors completely regressed in the presence of
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Figure 1. Growth of MCF7/HER2–18 xenograft tumors in athymic female mice treated with variable anti-HER single agents and combinations, with or
without ER targeted therapy. A, E2 treatment alone or with lapatinib (E2 þ L), trastuzumab (E2 þ T), or their combination (E2 þ L þ T). B, tamoxifen treatment
alone or with L (Tam þ L), T (Tam þ T), or their combination (Tam þ L þ T). C, tamoxifen treatment in the presence of estrogen with the combination
(E2 þ Tam þ L þ T). D, estrogen deprivation (ED) alone or along with L (ED þ L), T (ED þ T), or their combination (ED þ L þ T). E, tamoxifen treatment with
alternative combinations of HER family inhibitors—L and gefitinib (Tamþ LþG), double dose L 200mg/kg/d (Tamþ 2L), and tamoxifen with L and pertuzumab
(Tam þ L þ P). Complete regression was defined as complete tumor regression documented on 3 consecutive weekly measurements. Results are presented
as the mean tumor volume; error bars represent the standard error. B–E, for each group, the number of mice with complete tumor regression and the
total number of mice are shown.
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estrogen (13/13) and 92% completely regressed in its
absence (11/12; Fig. 2A and B, respectively). By day 231
of treatment, 4 out of the original 11 mice on the L alone
arm and 2 out of 11 mice on T alone arm had developed
resistant tumors. In contrast, none of the animals treated
with L þ T developed any tumors at any point during the
experiment. This again indicates the superiority of this
combination in BT-474 as well as in MCF7/HER2–18
tumors.
L þ T intermittent and reduced dose regimen in BT-
474 tumors
We next asked whether alternative treatment regimens of
(L þ T) with reduced dosing or changes in scheduling were
as effective as full continuous dosing.
As shown in Figure 3A and Table 2, several control
treatment groups from prior experiments were repeated
to ensure reproducibility of our results (E2, ED, L, T arms,
and L þ T), and all yielded similar results.
Short treatment duration for just 14 days led to CR in
80% of mice and median time to CR was similar to
continuous L þ T (35 days in both groups, P ¼ 0.72,
generalized Wilcoxon test). This indicates that the treat-
ment effect carried on beyond its brief duration, as
tumors continued to shrink after treatment was stopp-
ed. Although the rate of eventual TP was clearly higher
in this group (60% vs. 0%, P ¼ 0.001, generalized
Wilcoxon test), still this brief duration of treatment
resulted in prolonged tumor control with no TP in 6
out of 15 mice. Similarly, when treatment lasted just 42
days, CR rate and median time to CR were similar to full
L þ T but the rate of TP at 315 days was higher than with
continuous L þ T (27% vs. 0% TP, P ¼ 0.05, generalized
Wilcoxon test).
Figure 3B shows 2 alternate dosing methods, reduced
or intermittent dosing. Treatment with reduced dosing,
(1/2L þ 1/2T) led to CR in 93% of mice. Although, median
time to CR was longer compared with continuous full
dose L þ T (49 days vs. 35 days, respectively, P ¼ 0.03,
generalized Wilcoxon test), the rate of TP315 was not
significantly different (13% vs. 0%, respectively, P ¼ 0.18,
generalized Wilcoxon test). On the contrary, intermittent
treatment with L þ T (14 days on treatment and 14 days
off) led to CR and median time to CR similar to con-
tinuous full dose L þ T (100% and 35 days in both
groups). The difference in rate of TP between intermittent
versus full L þ T groups was not statistically significant
(14% vs. 0%, respectively, P¼ 0.17, generalized Wilcoxon
test).
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Figure 2.Growth of BT-474 xenograft tumors in athymic mice treated with
estrogen supplementation (E2) or estrogen deprivation (ED) alone or with
HER blocking agents. A, ED alone or along with lapatinib (ED þ L),
trastuzumab (ED þ T), or their combination (ED þ L þ T). B, continued E2
alone or with the combination of L and T (E2 þ L þ T). Results are
presented as the mean tumor volume; error bars represent the standard
error. For each group, the number of mice with complete tumor regression
and the total number of mice are shown. Complete regression was defined
as complete disappearance of the tumor for 3 consecutive weeks.
Table 1. Complete tumor response and time
to treatment resistance with variable treat-
ment combinations in MCF7/HER2–18 tumor
xenografts
Treatment Complete
tumor response
(%)
Time to
treatment
resistance
in days (95% CI)
E2 0 23 (14–43)
Tam 0 49 (24–60)
E2 þ L 0 44 (30–56)
E2 þ T 15 53 (39–68)
E2 þ L þ T 0 103 (42–136)
Tam þ T 15 115 (90–146)
Tam þ L 25 143 (122–174)
Tam þ 2L 0b 150 (122–NAa)
Tam þ L þ G 8 147 (109–NAa)
Tam þ L þ P 14 178 (138–NAa)
Tam þ L þ T 86 229 (170–342)
E2 þ Tam þ L þ T 58 182 (143–185)
Abbreviations: Tam, tamoxifen; E2, estrogen; T, trastuzu-
mab; L, lapatinib; G, gefitinib; P, pertuzumab.
a95% CI upper limit not achieved.
bSeveral animals had tiny nodules that did not satisfy the
definition of complete response.
Lapatinib and Trastuzumab in HER2-Positive Breast Cancer
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Effect of Lþ T on tumor cell proliferation and apoptosis
We next examined the effects of these treatments on
tumor cell proliferation, apoptosis, and key downstream
signaling intermediaries in the HER pathway.
Levels of p-HER2 were suppressed in MCF7/HER2–18
tumors from mice treated with L or T (Fig. 4A and B).
However, the combination L þ T was more potent in
inhibiting p-HER2 levels regardless of whether mice
received continued estrogen, ED, or Tam (Fig. 4A). The
same trends were noted in BT-474 tumors in which L and T
each inhibited p-HER2 individually but were more potent
in combination (Fig. 4C). Although total HER2 seems
reduced in both tumor models in mice treated with the
L þ T combination, this is likely related in part to tumor
shrinkage and tumor cell death. When corrected to pancy-
tokeratin, total HER2 was not significantly reduced in
animals treated with L þ T (data not shown).
Levels of p-MAPK were assessed in MCF7/HER2–18
(Fig. 4A, B, and D) and BT-474 tumors (Fig. 4C). Levels
of p-MAPK were significantly reduced in tumors from mice
receiving L, or T in addition to endocrine therapy in both
models (Fig. 4A, P ¼ 0.008 and 0.05; Fig. 4C, P ¼ 0.02 and
0.002, respectively, when compared with endocrine ther-
apy alone; Wilcoxon rank-sum test). Lþ T also significantly
reduced p-MAPK levels in both tumor models regardless of
endocrine therapy (Fig. 4A, P ¼ 0.02 compared with Tam;
Fig. 4B, P ¼ 0.05 compared with E2; Fig. 4C, P ¼ 0.002
compared with ED; Wilcoxon rank-sum test). Interestingly,
Figure 4A shows that L reduced p-MAPK more than L þ T.
However, p-MAPK assessment by IHC (Fig. 4D) shows that
in tumors from mice treated with Tam þ L þ T, p-MAPK
levels were significantly reduced than those observed in
Tam, Tam þ L, and Tam þ T (P ¼ 0.005, 0.019, and 0.039,
respectively, Wilcoxon rank-sum test). Similar significant
reductions in p-MAPK levels were observed in tumors from
mice treated with Tam þ L þ T in the presence of estrogen
(data not shown). In BT-474 tumors p-MAPK levels were
suppressed in tumors treated with both T and L as single
agents, and even more so with the combination (Fig. 4C).
These results indicate that L þ T is the most effective
regimen in reducing levels of p-MAPK.
Levels of p-Akt were assessed by Western blot and were
notably reduced in tumors receiving L, T, or their combina-
tion in both tumor models; MCF7/HER2–18 and BT-474
(Fig. 4A–C).
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Figure 3.Growth of BT-474 xenograft tumors in athymic mice treated with
estrogen supplementation (E2) or estrogen deprivation (ED) alone and with
lapatinib (L), trastuzumab (T), or their combination (L þ T) in various doses
and schedules. A, growth of tumors in animals treated with ED plus short
durations of Lþ T for 14 days (EDþ Lþ T 14) and 42 days (EDþ Lþ T 42)
compared with control groups treated with E2, ED, and ED þ L þ T. B,
growth of tumors treated with ED with full continuous Lþ T, reduced dose
therapy (1/2Lþ 1/2T), or intermittent therapy (EDþ Lþ T 14 on/off). For each
group, the number of mice with complete tumor regression and the total
number of mice are shown. Complete regression was defined as complete
disappearance of the tumor for 3 consecutive weeks.
Table 2. Complete response (CR), time to complete response (TCR), and tumor progression rate at
315 days (TP315) in treatment arms with alternate dosing/scheduling of lapatinib/trastuzumab in BT-474
tumor xenografts
Full L þ T T L 1/2L þ 1/2T L þ T 42 days L þ T 14 days L þ T 14 days on/off
N (mice) 13 19 13 15 15 15 14
Median TCR 35 63 70 49 42 35 35
Pa Ref 0.008 0.0003 0.03 0.58 0.72 0.46
CR (%) 100 89 77 93 100 80 100
TP315 (%) 0 16 46 13 28 60 14
Pa Ref 0.13 0.009 0.18 0.05 0.001 0.17
Abbreviations: T, trastuzumab; L, lapatinib.
aP value of generalized Wilcoxon test comparing other treatment groups to reference group (Ref).
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Figure 4. C, BT-474 xenograft tumors treated with ED alone or with L (ED þ L), T (ED þ T), or their combination (ED þ L þ T). Proteins from tumor lysates
were separated by SDS PAGE and subjected to immunoblot analysis with antibodies specific to total HER2, total Akt, total MAPK, p-HER2 (at Tyr1248), p-Akt (at
Thr308) andp-p44/42MAPK (atThr202andTyr204), orb-actin.Protein expressionandphosphorylation levelswerequantifiedbyOdyssey Infrared ImagingSystem.
In each tumor, protein levels were normalized to the level of b-actin (the loading-control; by the formula, protein level/actin level  100). For each treatment arm,
protein expression levels were compared with control group (Tam, E2, and ED) as 1.00. D, immunohistochemistry studies on MCF7/HER2–18 xenografts: the
pictures on the left are representative images of each biomarker staining. The panels on the left are quantitative representations of biomarker expression. 1,
expression of p-p44/42 MAPK (at Thr202 and Tyr204) in MCF7/HER2–18 xenograft tumors treated with E2, Tam alone, or with L (Tam þ L), T (Tamþ T), and the
combination (Tamþ Lþ T). The length of treatment was 3 days. Levels of p-MAPKwere assessed by immunohistochemical staining and reported using the Allred
Score.Therewereat least 8 tumors fromeachgroup. 2, cell proliferation:BrDUstainingwasused tomeasurecell proliferation. Proliferationwasmeasured in tumors,
8 from each treatment group, after 3 days of treatment. Results are the percentage of cells positive for BrDU. 3, apoptosis levels of cleaved caspase 3/7
were assessed immunohistochemically by use of an antibody against cleaved caspase 3/7 after day 3 of treatment. Apoptosis was measured in at least 8 tumors
from each treatment group. Results are the percentage of cells positive for cleaved caspase 3/7. In all panels, error bars represent the standard error.
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The relative effect of Lþ T on proliferation and apoptosis
was investigated. Proliferation was assessed using BrDU
uptake after 3 days of treatment in MCF/HER2–18 tumor
xenografts (Fig. 4D). Neither L nor T significantly reduced
the proliferative fraction when added to Tam (P¼ 0.54 and
0.10, respectively, Wilcoxon rank-sum test). However, the L
þ T combination caused a significant reduction in BrDU
uptake in comparison to Tam alone, Tam þ L, or Tam þ T
(P ¼ 0.007, 0.007, and 0.016, respectively, Wilcoxon rank-
sum test). Similar results were noted in BT-474 xenografts
as well (data not shown).
Apoptosis was assessed by IHC at day 3 by an antibody
that detects cleaved caspase 3 and 7. Figure. 4D shows that
in MCF7/HER2–18 xenografts, neither L nor T resulted in
any significant change in apoptosis (P ¼ 0.57 and 0.61,
respectively, Wilcoxon rank-sum test). However, when L þ
T were used in combination, a significant increase in
apoptosis was observed over Tam alone or Tam þ L (P
¼ 0.032 and 0.0097, respectively, Wilcoxon rank-sum test).
In BT-474 xenografts, a trend of increased apoptosis in the
T and L þ T treatment groups over Tam or Tam þ L was
noted, but was not statistically significant.
Discussion
Trastuzumab is effective in several clinical settings
(11, 12), and recent data suggest that the population
of patients that benefit from T therapy may be expanding
(32). However, de novo and acquired resistance to T
remain a challenge in clinical management. One strategy
to overcome resistance is a more complete blockade
of HER2 signaling using a combination of HER2 inhibi-
tors. At the same time, identifying optimal duration of
this blockade could lead to reduced treatment cost and
enhanced quality of life if prolonged therapy is not
necessary.
Lapatinib, a dual tyrosine kinase inhibitor of HER1 and
2, should block the HER receptors more completely than T,
which is most effective in inhibiting HER2 homodimers.
Furthermore, L inhibits p95, the constitutively active short
form of HER2 against which T is ineffective. The data
presented here using 2 different in vivomodel systems show
that neither L nor T alone are as effective as their combina-
tion in antagonizing HER2 related signaling pathways or
inducing tumor regression. The combination of the 2 drugs
provides more potent inhibition of downstream signals,
more effective inhibition of cell proliferation, and possibly
greater induction of apoptosis than each as a single agent.
Our findings support our prior report of the remarkable
efficacy of a 3-drug cocktail of HER inhibitors in tumor
xenografts in mice (21) and they provide additional ratio-
nale for a combination regimen of the 2 approved drugs
now in clinical testing.
Our data also provide mechanistic insights into the
optimal method to block the HER pathway at the receptor
level. L was expected to be amore complete inhibitor of the
pathway but the antitumor effects of the drug were insuffi-
cient as a single agent in both MCF7/HER2–18 and BT-474
tumors. Adding G to L for added HER1 inhibition, dou-
bling the L dose, and substituting P for T to block HER2
heterodimerization were much less effective in causing
complete tumor regressions and delaying TTR than was
the combination of L with T.
Data from our group evaluating human HER2-over-
expressing breast cancer samples of patients obtained
from 2 neoadjuvant clinical trials treated with single
agent T or L showed that tumors with low PTEN or
mutated PI3KCA are resistant to T but sensitive to L
(33). These findings along with evidence from other
groups and the present data indicate that L and T may
exert their effect via distinct but complementary mechan-
isms of action (34, 35).
After demonstrating the efficacy of the combination of L
and T, we investigated the effect of dose reduction, inter-
mittent delivery, or shortened duration of the standard
combination. Given the promising results from a clinical
study in patients treated with short term T (36) and our
prior observation that T, like chemotherapy, induces apop-
tosis in tumors from patients undergoing neoadjuvant
therapy (37), in the current study we reasoned that a brief
course of combined L þ T might still be very effective.
Our results showed that even when treatment was given
for a short course (14 days), tumor regression continued
after stopping the therapy, and the majority of mice had a
CR with 40% of mice without TP315. When treatment
duration was extended to 42 days, the proportion of mice
without TP315 increased to 72%. Thus, whereas longer
therapy may be optimal, these very short exposures were
still very effective, suggesting that shorter treatment dura-
tions should be explored in patients.
We also show that a reduction of the dose of both L and T
(1/2 L þ 1/2 T) effectively blocks the HER pathway and is as
effective as full doses in eradicating tumors. Furthermore,
the schedule of intermittent therapy which lowered the
dose intensity by half was just as effective.
Although it is difficult to extrapolate these treatment
doses and durations directly to patients, the cumulative
data suggests that these or similar strategies should be
tested in patients. There is increasing emphasis on reducing
toxicity from unnecessary treatment. A recent clinical trial
of L þ T with paclitaxel had to be stopped early due to
significant toxicity, especially diarrhea (38). This, together
with economic implications of the rising cost of cancer
care, highlights the potential impact of our results. Clinical
trials comparing the standard 1-year approach to shorter
and intermittent dosing schedules should be explored. If as
effective as standard therapy, these alternative schedules
would significantly lower the cost and toxicity of treatment.
Our molecular studies show that the combination of L
and T reduces p-HER more effectively than either agent
alone.
In addition, the L þ T combination inhibits down-
stream signaling through 2 important cell proliferation
and survival pathways mediated through AKT and MAPK,
thus explaining the increased antitumor activity of the
combination. Our finding of a significant reduction in
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proliferation and increased apoptosis in the L þ T-treated
tumors over those treated with a single agent also supports
this conclusion.
In addition to direct potent inhibition of HER signaling,
the combination may be working by other mechanisms.
There are data showing that L stabilizes different HER
dimers, which are then internalized after T binding to
HER2 (19). In addition, there is mounting evidence that
both agents are active against tumor-initiating cells, which
may explain tumor xenograft elimination in some animals
in our study (39, 40)
Our data, derived from experimental models, may not
represent the totality of HER2-overexpressing breast can-
cers in patients. Both our models are ER-positive, although
established BT-474 xenografts are not estrogen dependent
(21). However, our findings have important and compel-
ling clinical implications.
In addition to lending support for clinical trials studying
the combination of L and T, our findings strongly argue for
timely clinical testing of intermittent dosing of this com-
bination. As personalized cancer therapy becomes the new
standard of care in oncology, it is a high priority to
combine optimal therapeutic strategies with minimal toxi-
city and cost.
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